129 related articles for article (PubMed ID: 11772255)
1. Src inhibitors: genomics to therapeutics.
Sawyer T; Boyce B; Dalgarno D; Iuliucci J
Expert Opin Investig Drugs; 2001 Jul; 10(7):1327-44. PubMed ID: 11772255
[TBL] [Abstract][Full Text] [Related]
2. Novel bone-targeted Src tyrosine kinase inhibitor drug discovery.
Shakespeare WC; Metcalf CA; Wang Y; Sundaramoorthi R; Keenan T; Weigele M; Bohacek RS; Dalgarno DC; Sawyer TK
Curr Opin Drug Discov Devel; 2003 Sep; 6(5):729-41. PubMed ID: 14579523
[TBL] [Abstract][Full Text] [Related]
3. Targeting protein kinases for bone disease: discovery and development of Src inhibitors.
Metcalf CA; van Schravendijk MR; Dalgarno DC; Sawyer TK
Curr Pharm Des; 2002; 8(23):2049-75. PubMed ID: 12171518
[TBL] [Abstract][Full Text] [Related]
4. Basis and importance of Src as a target in cancer.
Levin VA
Cancer Treat Res; 2004; 119():89-119. PubMed ID: 15164875
[No Abstract] [Full Text] [Related]
5. Structural basis of Src tyrosine kinase inhibition with a new class of potent and selective trisubstituted purine-based compounds.
Dalgarno D; Stehle T; Narula S; Schelling P; van Schravendijk MR; Adams S; Andrade L; Keats J; Ram M; Jin L; Grossman T; MacNeil I; Metcalf C; Shakespeare W; Wang Y; Keenan T; Sundaramoorthi R; Bohacek R; Weigele M; Sawyer T
Chem Biol Drug Des; 2006 Jan; 67(1):46-57. PubMed ID: 16492148
[TBL] [Abstract][Full Text] [Related]
6. Structural analysis of the lymphocyte-specific kinase Lck in complex with non-selective and Src family selective kinase inhibitors.
Zhu X; Kim JL; Newcomb JR; Rose PE; Stover DR; Toledo LM; Zhao H; Morgenstern KA
Structure; 1999 Jun; 7(6):651-61. PubMed ID: 10404594
[TBL] [Abstract][Full Text] [Related]
7. Synthetic SRC-kinase domain inhibitors and their structural requirements.
Schenone S; Manetti F; Botta M
Anticancer Agents Med Chem; 2007 Nov; 7(6):660-80. PubMed ID: 18045061
[TBL] [Abstract][Full Text] [Related]
8. Progress in the development of inhibitors of SH2 domains.
Cody WL; Lin Z; Panek RL; Rose DW; Rubin JR
Curr Pharm Des; 2000 Jan; 6(1):59-98. PubMed ID: 10637372
[TBL] [Abstract][Full Text] [Related]
9. Recent advances in the design and synthesis of SH2 inhibitors of Src, Grb2 and ZAP-70.
Vu CB
Curr Med Chem; 2000 Oct; 7(10):1081-100. PubMed ID: 10911019
[TBL] [Abstract][Full Text] [Related]
10. SRC homology-2 inhibitors: peptidomimetic and nonpeptide.
Sawyer TK; Bohacek RS; Dalgarno DC; Eyermann CJ; Kawahata N; Metcalf CA; Shakespeare WC; Sundaramoorthi R; Wang Y; Yang MG
Mini Rev Med Chem; 2002 Oct; 2(5):475-88. PubMed ID: 12370048
[TBL] [Abstract][Full Text] [Related]
11. Bone-targeted Src kinase inhibitors: novel pyrrolo- and pyrazolopyrimidine analogues.
Sundaramoorthi R; Shakespeare WC; Keenan TP; Metcalf CA; Wang Y; Mani U; Taylor M; Liu S; Bohacek RS; Narula SS; Dalgarno DC; van Schravandijk MR; Violette SM; Liou S; Adams S; Ram MK; Keats JA; Weigle M; Sawyer TK; Weigele M
Bioorg Med Chem Lett; 2003 Sep; 13(18):3063-6. PubMed ID: 12941334
[TBL] [Abstract][Full Text] [Related]
12. Design of allele-specific inhibitors to probe protein kinase signaling.
Bishop AC; Shah K; Liu Y; Witucki L; Kung C; Shokat KM
Curr Biol; 1998 Feb; 8(5):257-66. PubMed ID: 9501066
[TBL] [Abstract][Full Text] [Related]
13. Src kinase inhibitors: an emerging therapeutic treatment option for prostate cancer.
Edwards J
Expert Opin Investig Drugs; 2010 May; 19(5):605-14. PubMed ID: 20367532
[TBL] [Abstract][Full Text] [Related]
14. Novel patented SRC kinase inhibitor.
Lu XL; Liu XY; Cao X; Jiao BH
Curr Med Chem; 2012; 19(12):1821-9. PubMed ID: 22414081
[TBL] [Abstract][Full Text] [Related]
15. The many faces of Src: multiple functions of a prototypical tyrosine kinase.
Schwartzberg PL
Oncogene; 1998 Sep; 17(11 Reviews):1463-8. PubMed ID: 9779992
[TBL] [Abstract][Full Text] [Related]
16. PH006, a novel and selective Src kinase inhibitor, suppresses human breast cancer growth and metastasis in vitro and in vivo.
Ma JG; Huang H; Chen SM; Chen Y; Xin XL; Lin LP; Ding J; Liu H; Meng LH
Breast Cancer Res Treat; 2011 Nov; 130(1):85-96. PubMed ID: 21181437
[TBL] [Abstract][Full Text] [Related]
17. Natural product inhibitors of protein-protein interactions mediated by Src-family SH2 domains.
Sperl B; Seifert MH; Berg T
Bioorg Med Chem Lett; 2009 Jun; 19(12):3305-9. PubMed ID: 19427202
[TBL] [Abstract][Full Text] [Related]
18. Targeting the yin and the yang: combined inhibition of the tyrosine kinase c-Src and the tyrosine phosphatase SHP-2 disrupts pancreatic cancer signaling and biology in vitro and tumor formation in vivo.
Gomes EG; Connelly SF; Summy JM
Pancreas; 2013 Jul; 42(5):795-806. PubMed ID: 23271399
[TBL] [Abstract][Full Text] [Related]
19. The SH2 domain: versatile signaling module and pharmaceutical target.
Machida K; Mayer BJ
Biochim Biophys Acta; 2005 Feb; 1747(1):1-25. PubMed ID: 15680235
[TBL] [Abstract][Full Text] [Related]
20. SAR of carbon-linked, 2-substituted purines: synthesis and characterization of AP23451 as a novel bone-targeted inhibitor of Src tyrosine kinase with in vivo anti-resorptive activity.
Shakespeare WC; Wang Y; Bohacek R; Keenan T; Sundaramoorthi R; Metcalf C; Dilauro A; Roeloffzen S; Liu S; Saltmarsh J; Paramanathan G; Dalgarno D; Narula S; Pradeepan S; van Schravendijk MR; Keats J; Ram M; Liou S; Adams S; Wardwell S; Bogus J; Iuliucci J; Weigele M; Xing L; Boyce B; Sawyer TK
Chem Biol Drug Des; 2008 Feb; 71(2):97-105. PubMed ID: 18179464
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
